Carbamazepine‐Induced Severe Cutaneous Adverse Drug Reactions: A 21‐Year Comparison Between Children and Adults in Malaysia

Severe cutaneous adverse drug reactions (SCARs) are a life‐threatening condition. We aimed to identify all carbamazepine‐induced SCARs voluntarily reported to the Malaysian pharmacovigilance database and to compare between children and adults. Adverse drug reaction reports for carbamazepine were extracted from 2000 to 2020, and divided into 2 groups, that is, children (aged 0–17 years) and adults (aged 18 years and above). Age, sex, race, and carbamazepine dose were analyzed using multiple logistic regression. Of 1102 carbamazepine adverse drug reaction reports, 416 reports were SCARs (99 children, 317 adults). Stevens–Johnson syndrome and toxic epidermal necrolysis were the main SCAR types for both age groups. Median time‐to‐onset for any type of SCAR was 13 days, regardless of age. In children, Malay individuals were 3.6 times more likely to report SCARs (95% confidence interval, 1.356–9.546; P = .010) compared to the Chinese population. In adults, carbamazepine‐induced SCARs were reported as 3.6 times higher in those with a daily dose of 200 mg or less as compared to a daily dose of 400 mg or more. (95% confidence interval, 2.257–5.758; P < .001) Carbamazepine‐induced SCARs reported in Malaysia were predominantly Stevens–Johnson syndrome or toxic epidermal necrolysis, with the majority in Malay individuals. Initiation therapy needs close monitoring between 2 weeks and 1 month.

[1]  P. Lai,et al.  Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia , 2022, Journal of clinical pharmacology.

[2]  C. Sung,et al.  Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care , 2020, Frontiers in Pharmacology.

[3]  L. Cavallari,et al.  Is universal HLA‐B*15:02 screening a cost‐effective option in an ethnically diverse population? A case study of Malaysia , 2017, The British journal of dermatology.

[4]  H. Tan,et al.  Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription , 2017, Case reports in dentistry.

[5]  T. Craig,et al.  HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese , 2015, Asia Pacific allergy.

[6]  P. Kwan,et al.  Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions , 2014, Neurology.

[7]  D. Juurlink,et al.  Recurrence and mortality following severe cutaneous adverse reactions. , 2014, JAMA.

[8]  M. Alomar.  Factors affecting the development of adverse drug reactions (Review article). , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[9]  Y. Cheung,et al.  Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore , 2013, Archives of Disease in Childhood.

[10]  W. Tassaneeyakul,et al.  Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. , 2013, JAMA dermatology.

[11]  N. Shear,et al.  Cutaneous Drug Reactions in Children: An Update , 2013, Pediatric Drugs.

[12]  M. Rieder.  New ways to detect adverse drug reactions in pediatrics. , 2012, Pediatric clinics of North America.

[13]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[14]  Tschung-il Kim,et al.  Clinical Characteristics of Severe Cutaneous Adverse Reactions in a tertiary hospital in Korea , 2012 .

[15]  G. Koren,et al.  Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children , 2011, Pediatrics.

[16]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[17]  S. Murad,et al.  Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.

[18]  P. Kwan,et al.  Association of HLA-B*1502 allele and carbamazepine- induced severe adverse cutaneous drug reaction among Asians, a review , 2008 .

[19]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[20]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[21]  J. Pellock,et al.  Risk-Benefit Assessment of Carbamazepine in Children , 1991, Drug safety.

[22]  S. Grover.  Severe cutaneous adverse reactions. , 2011, Indian journal of dermatology, venereology and leprology.

[23]  S. Jick,et al.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. , 1990, Archives of dermatology.